About Us > Kanu Sharan, MD

Kanu Sharan, MD

Placeholder silhouette

Highlights

  • Doctor and assistant professor of medicine at MD Anderson Cancer Center at Cooper
  • Board certified in internal medicine and hematology and medical oncology
featured_paragraph

Dr. Sharan is a doctor and assistant professor of medicine at MD Anderson Cancer Center at Cooper, in Camden, New Jersey. She is board certified in internal medicine and hematology and medical oncology, and she has research interests in breast cancer, leukemia, lymphoma, benign hematology and general hematology/oncology.

general_content

Dr. Sharan completed her medical degree at Lady Hardinge Medical College in India, her residency at Graduate Hospital in Philadelphia, and a fellowship at Thomas Jefferson University Hospital in Philadelphia.

contributions_carousel

Contributions

Medicines to protect bones

05/29/24 | BY: Adam Brufsky, Kanu Sharan

In addition to lifestyle changes you can make to help keep your bones healthy, there are certain medicines that can be taken to stop bone loss.

Read More
 | 7 Min. Read |

Targeted therapy for HER2-positive breast cancer

05/28/24 | BY: Kanu Sharan

Targeted treatments for HER2-positive breast cancer target the HER2 proteins on or within cancer cells that help the cells to grow. They attach to HER2 proteins and block signals that tell the cells to multiply too quickly.

Read More
 | 4 Min. Read |

Pertuzumab benefits some when given with Herceptin

10/24/17 | BY: Eric Fitzsimmons

Adding the targeted therapy pertuzumab (Perjeta) to standard anti-HER2 treatment for early-stage, HER2-positive breast cancer resulted in more people living at least 3 years without a recurrence.

Read More
 | 7 Min. Read

Improving bone health

05/15/17 | BY: Adam Brufsky, Kanu Sharan

Bone health factors like build, family history, and medications are beyond control. However, personal efforts can enhance bone health despite these.

Read More
 | 6 Min. Read

Bone health

05/15/17 | BY: Adam Brufsky, Kanu Sharan

Get tips on ways to protect your bones during breast cancer treatment by making healthy life choices and, if necessary, by taking bone-protecting medicines.

Read More
 | 10 Min. Read |

After DCIS, Some Women Face Lower Quality of Life

08/16/16 | BY: Eric Fitzsimmons

A study found that within 2 years of diagnosis, most women who have had DCIS enjoyed a quality of life similar to that of peers who had no cancer. But it also showed a trend to worse mental well-being in younger women shortly after diagnosis and all women 10 or more years after diagnosis.

Read More
 | 8 Min. Read

Everolimus

08/31/15 | BY: Kanu Sharan

Everolimus (Afinitor) is an mTOR inhibitor, halting cancer cell division and potentially impeding tumor growth by blocking new blood vessel formation, crucial for tumor expansion.

Read More
 | 5 Min. Read